Inotiv, Inc. Announces Expansion of Safety Assessment Offerings with Acquisition of Integrated Laboratory Systems, LLC
January 10 2022 - 8:33AM
Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or
“Inotiv”), a leading contract research organization
specializing in nonclinical and analytical drug discovery and
development services and research models and related products and
services, today announced that the Company has completed the
purchase of Integrated Laboratory Systems, LLC (“ILS”), a portfolio
company of Sier Capital Partners (“Sier Capital”). ILS is a
contract research organization, located in Morrisville, North
Carolina, specializing in genetic toxicology, in vivo and in
vitro toxicology, pathology, molecular biology, bioinformatics and
computational toxicology services.
Transaction consideration totaled $56.0 million, consisting of:
$38.0 million in cash and 429,118 Inotiv common shares having a
value of $18.0 million based on the volume weighted average closing
price of Company shares as reported by NASDAQ for the twenty
trading-day period ending on January 6, 2022. ILS operates in two
leased facilities with a total of 50,000 square feet, including a
vivarium that is accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care, and recognized revenue of
approximately $20.0 million in 2021.
“The addition of ILS to Inotiv adds immediate scale to our
developing genetic toxicology services,” said Greg Beattie,
Inotiv’s Chief Operating Officer. “ILS will also provide additional
capacity and growth opportunities for Inotiv. This acquisition
expands our in vivo and in vitro toxicology services, including the
addition of significant pathology and toxicology expertise, and it
extends our services into genomics, bioinformatics and
computational toxicology. These capabilities broaden our market
reach and create significant new cross-selling opportunities.”
“We are very excited to become part of Inotiv,” added ILS’s
President, David Allen. “Our clients’ needs are evolving, and
joining Inotiv allows us to collectively offer a comprehensive
solution to our clients that we’ve lacked until today. We’re eager
to join a team that will offer a full suite of IND-enabling
pharmacology and toxicology studies.”
John Sagartz, Inotiv’s Chief Strategy Officer, commented,
“Demand continues to be very strong for our toxicology services,
and the addition of ILS not only allows us to add capacity in
significant strategic areas, it also adds industry-recognized
thought leaders that will help us continue to expand our services
and broaden our consultative problem-solving approach. We believe
we will be able to expand the existing capacity at ILS and further
build upon our infrastructure as we have done with previous
acquisitions.”
Dr. Sagartz continued, “We began our entry into genetic
toxicology with our acquisition of assets from MilliporeSigma’s
BioReliance portfolio in July 2021, and are moving forward rapidly
in establishing these capabilities at our new facility in
Rockville, MD. Combined with ILS’s GLP-compliant ‘standard battery’
of genetic toxicology testing and mechanistic genetic toxicology
assays to support liability management, Inotiv has now filled what
had been a strategic gap in our offerings. We intend to become a
leading provider of genetic toxicology services worldwide.”
The acquisiton of ILS will provide clients the following
benefits:
- Genetic toxicology testing, including mechanistic assays to
address liability issues
- Expert toxicologists to consult with clients to address genetic
toxicology concerns
- Expanded capacity for rodent toxicology studies
- Government contracting expertise and infrastructure
leverageable to other Inotiv services
- Additional board-certified veterinary pathologists and
board-certified toxicologists
- Expertise in computational and in vitro approaches for
predictive toxicology assessments
The Company expects to retain all existing ILS
employees.
Edgemont Partners served as the exclusive
financial advisor for Sier Capital and ILS in connection with the
transaction.
About Inotiv
Inotiv, Inc. is a leading contract research
organization dedicated to providing nonclinical and analytical drug
discovery and development services and research models and related
products and services. The Company’s products and services focus on
bringing new drugs and medical devices through the discovery and
preclinical phases of development, all while increasing efficiency,
improving data, and reducing the cost of taking new drugs to
market. Inotiv is committed to supporting discovery and development
objectives as well as helping researchers realize the full
potential of their critical R&D projects, all while working
together to build a healthier and safer world. Further information
about Inotiv can be found here: https://www.inotivco.com/.
About ILS
Integrated Laboratory Systems, LLC is a contract
research organization providing research and testing services to
the pharmaceutical, chemical, agrochemical, food additive, and
consumer product industries as well as to the Federal government.
ILS conducts investigative toxicology, genetic toxicology,
computational toxicology, histology, pathology, molecular biology,
and information science services tailored to meet our clients'
needs. ILS uses a flexible and comprehensive service model to
provide a full suite of scientific services compliant with national
and international regulatory requirements to ensure the highest
quality products. Further information about ILS can be found here:
www.ils-inc.com.
About Sier Capital
Sier Capital is a private investment firm backing exceptional
management teams. Sier focuses on control acquisitions and
management buyouts of companies generating between $2-$10 million
of annual EBITDA. Further information about Sier Capital can be
found at https://siercapital.com/.
This release may contain forward-looking
statements that are subject to risks and uncertainties including,
but not limited to, risks and uncertainties related to changes in
the market and demand for our products and services, the
development, marketing and sales of products and services, changes
in technology, industry and regulatory standards, the timing of
acquisitions and the successful closing, integration and business
and financial impact thereof, the impact of the COVID-19 pandemic
on the economy, demand for our services and products and our
operations, including the measures taken by governmental
authorities to address the pandemic, which may precipitate or
exacerbate other risks and/or uncertainties, expansion and related
efforts, and various other market and operating risks, including
those detailed in the Company's filings with the U.S. Securities
and Exchange Commission.
Company Contact |
|
Investor Relations |
Inotiv, Inc. |
|
The Equity Group Inc. |
Beth A. Taylor, Chief Financial Officer |
|
Kalle Ahl, CFA |
(765) 497-8381 |
|
(212) 836-9614 |
btaylor@inotivco.com |
|
kahl@equityny.com |
|
|
|
|
|
Devin Sullivan |
Sier Capital Contact |
|
(212) 836-9608 |
Adam Altusaaltus@siercapital.com |
|
dsullivan@equityny.com |
Inotiv (NASDAQ:NOTV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Inotiv (NASDAQ:NOTV)
Historical Stock Chart
From Apr 2023 to Apr 2024